Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Phase 3

A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

NCT07881432 · tracked via the Priya Life Science Germany tracker
Phase
Phase 3
Started
2026-12
Last updated
2026-10-19

Condition(s) studied

Obesity

Investigational drug(s) / intervention(s)

eloralintide and tirzepatide →Eloralintide →Tirzepatide →Placebo

eloralintide and tirzepatide: Administered SC

Eloralintide: Administered SC

Tirzepatide: Administered SC

Placebo: Administered SC

Study summary

The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity.

Participation in the study will last about 2 years.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Have a stable self-reported body weight (\<5% body weight change) for 90 days prior to screening * Have a BMI of ≥35 kg/m2 at screening * Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight Exclusion Criteria: * Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening) * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening) * Have type 1 diabetes, type 2 diabetes, or any other type of diabetes * Have had within 90 days prior to screening: * heart attack * stroke * coronary artery revascularization * unstable angina, or * hospitalization due to congestive heart failure * Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure * Have taken any glucose-lowering medication within 90 days of screening * Have taken medications or alternative remedies intended for weight loss within 90 days of screening

Primary outcome measure(s)

  • Percent Change from Baseline in Body Weight — Baseline, Week 100

Trial sites (155)

FacilityCityRegionStatus
Care Access - 801 South Power Road, Mesa Mesa Arizona
Headlands Research - Scottsdale Scottsdale Arizona
Tucson Clinical Research Institute Tucson Arizona
Valley Clinical Trials, Inc. Covina California
Los Angeles Institute for Metabolic Research Los Angeles California
Peninsula Research Associates Rolling Hills Estates California
Artemis Institute for Clinical Research San Diego California
Southern California Clinical Research Santa Ana California
Yale University School of Medicine New Haven Connecticut
JEM Research Institute Atlantis Florida
K2 Medical Research - Maitland Maitland Florida
Flourish Research - Miami, LLC Miami Florida
Care Access - Tamarac Tamarac Florida
Care Access - Tampa Tampa Florida
Care Access - Dalton Walmart Dalton Georgia
Teak Research Consults - Dunwoody Dunwoody Georgia
Clinical Research Atlanta Stockbridge Georgia
Rophe Adult and Pediatric Medicine/SKYCRNG Union City Georgia
East-West Medical Research Institute Honolulu Hawaii
IMA Clinical Research Chicago Chicago Illinois
DM Clinical Research - Indianapolis Indianapolis Indiana
Care Access - Eunice Eunice Louisiana
Clinical Trials Management, LLC d/b/a Flourish Research Metairie Louisiana
Pharmasite Research, Inc. Baltimore Maryland
Care Access - Baltimore Baltimore Maryland
Brigham and Women's Hospital Diabetes Program Boston Massachusetts
SKY Integrative Medical Center/SKYCRNG Ridgeland Mississippi
IMA Clinical Research Las Vegas Las Vegas Nevada
Palm Research Center Sunset Las Vegas Nevada
IMA Clinical Research Albuquerque Albuquerque New Mexico
NYC Research INC Long Island City New York
Weill Cornell Medical College New York New York
IMA Clinical Research NYC Midtown New York New York
University of North Carolina Medical Center Chapel Hill North Carolina
Medication Management Greensboro North Carolina
Care Access - Raleigh Raleigh North Carolina
Clinical Research of Philadelphia Philadelphia Pennsylvania
Keystone Clinical Studies Plymouth Meeting Pennsylvania
Clinical Neuroscience Solutions Inc. Memphis Tennessee
JCCT - Juno Bellaire Site Bellaire Texas

+ 115 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07881432 on ClinicalTrials.gov ↗ ← All trials in Germany